Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03755726

A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,200 (estimated)
Sponsor
Centre Hospitalier de PAU · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. The network that will emerge will finally lead to the opportunity of setting up therapeutic trials and establishing recommendations based on solid scientific evidence.

Detailed description

Malignant hypertension is the most severe form of high blood pressure, fatal if left untreated. It has not disappeared, with an increasing incidence. Patients with the disease, mainly young (35 to 55 years of age), have an unfavorable cardiovascular prognosis (14% of cardiovascular and renal events at 4 years). Despite these facts, scientific research on the subject remains limited. The definitions and diagnostic criteria have not changed since 1929, and the therapeutic recommendations remain empirical. This first prospective and multicentric registry will increase and modernize the knowledge of the disease. From these data, diagnostic and therapeutic recommendations based on solid scientific evidence could be developed. The investigators want to first recruit 500 patients and define their prognosis at 5 years. The impact of the patient's phenotype, type and number of target organs affected will be studied. A modern definition, adapted to these results, could be proposed. The epidemiology of the disease, the care pathways, the target organ disorders and the management carried out in the centers will be described in detail.

Conditions

Timeline

Start date
2019-09-20
Primary completion
2034-09-20
Completion
2034-09-20
First posted
2018-11-28
Last updated
2026-03-23

Locations

37 sites across 2 countries: France, Poland

Source: ClinicalTrials.gov record NCT03755726. Inclusion in this directory is not an endorsement.